Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Influenza Antilichaam resultaten
Volgen
PRESS RELEASE Crucell Announces Excellent Results for Influenza Antibody Leiden, The Netherlands, 11 December 2008 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that its monoclonal antibody (mAb) directed against a broad range of influenza virus strains has strongly outperformed the most current anti-influenza drug in preclinical tests. The latest results were presented yesterday, by Dr Jaap Goudsmit, at IBC's 19th Annual International Conference on Antibody Engineering in San Diego, USA. The preclinical study compared Crucell's mAb CR6261 with the anti-influenza drug oseltamivir in terms of their value for flu prevention and treatment. The flu strains tested included the 'bird flu' strain H5N1, which, experts fear, has the potential to cause a pandemic, and H1N1, which is similar to the strain responsible for the devastating pandemic in 1918. Dr Goudsmit presented data showing that the mAb CR6261 was 100% successful in preventing infection with H5N1. When given after H5N1 infection, Crucell's mAb demonstrated the ability to prevent death and cure disease in all cases. The mAb also performed significantly better for the prevention and treatment of H1N1 infection, illustrating the potential use for seasonal applications as well. This makes it a potentially powerful antibody against a broad range of influenza strains. Fears of a flu pandemic are fuelled by the rising number of flu strains that have mutated in ways that make them resistant to oseltamivir. Importantly, the study showed that CR6261 provides immediate protection against the influenza virus, suggesting that it will be able to prevent disease spread. In contrast, oseltamivir was less efficacious and in some cases not effective at all. The advantages of the mAb over oseltamivir may also be important for protecting or treating people at risk of severe illness or death due to seasonal flu. These include the elderly and immune-suppressed individuals. The characterization of the antibody will be described in the online journal PLoS ONE (www.plos.org) on December 16, 2008. "An effective treatment of influenza is urgently needed. The limited efficacy of oseltamivir and the rising resistance to this anti-influenza drug are cause for concern. I am very encouraged by these preclinical results indicating that our monoclonal antibody may provide an effective means for disease prevention and cure," said Jaap Goudsmit, Crucell's Chief Scientific Officer. "Although this antibody is still at any early stage of development, these results are very promising and demonstrate the strength of our in-house research and development aimed at bringing innovation to global health," said Ronald Brus, Crucell's Chief Executive Officer. About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com. Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on May 7, 2008, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards (IFRS). For further information please contact: Crucell N.V. Oya Yavuz Director Corporate Communications & Investor Relations Tel. +31-(0)71-519 7064ir@crucell.com www.crucell.com Crucell N.V. Archimedesweg 4-6 PO Box 2048 2301 CA Leiden The Netherlands To unsubscribe from this distribution, please use the URL below:thomlets.ccbn.com/MessagingWeb/Unsubs... -----
Die had ik over het hoofd gezien. Dubbele post weggehaald. PB Excellent Results for Influenza Antibody!!! "The mAb also performed significantly better for the prevention and treatment of H1N1 infection, illustrating the potential use for seasonal applications as well". "given after H5N1 infection, Crucell's mAb demonstrated the ability to prevent death and cure disease in all cases. " "....has strongly outperformed the most current anti-influenza drug in preclinical tests."
AMSTERDAM (Dow Jones)--Crucell nv heeft goede resultaten bereikt met antilichaam mAb CR6261 tegen verschillende griepvirussen, in vergelijk met gangbare antilichamen. Dat meldt het Nederlandse biotechbedrijf donderdag in een persbericht. Crucell vergeleek antilichaam mAb CR6261 in een pre-klinische studie met anti-griepmedicijn oseltamivir op hun mogelijkheden om griep te voorkomen en te behandelen. Onder de griepvirussen waarop Crucell's antilichaam is getest, was onder andere het 'vogelgriepvirus' H5N1 waarvan deskundigen vrezen dat het zich kan uitbreiden naar een pandemie. Dit virus lijkt op het verwoestende H1N1-virus dat in 1918 veel doden veroorzaakte. mAb CR6261 bleek 100% succesvol in de preventie van besmetting met H5N1. Na infectie bleek het antilichaam ook in staat dood te kunnen voorkomen en de ziekte in alle gevallen te genezen. Ook bleek het antilichaam van Crucell beter in staat het H1N1-virus te voorkomen en te behandelen dan bestaande antilichamen. De studie toonde eveneens aan dat het antilichaam onmiddellijke bescherming biedt tegen het griepvirus, waardoor het vermoedelijk in staat is verspreiding van de ziekte te voorkomen. Hierop presteerde oseltamivir minder goed, zo meldt het persbericht. Gisteren presenteerde Jaap Goudsmit de resultaten op een seminar in San Diego. Het antilichaam zal uitgebreid beschreven worden in het online magazine Plos One op 16 december.
Heel mooi nieuws. Giseren was er rond 12 uur wel een spike omhoog tot ruim boven de 11. Dat zal het moment geweest zijn van die presentatie van Jaap. PB een dag te laat dus? Zal dit de koers. Vandaag ruim boven de 11 sluiten als het mee zit.
De annalisten kunnen hier niet meer omheen,word het een strong buy
Mr Greenspan schreef:
Heel mooi nieuws. Giseren was er rond 12 uur wel een spike omhoog tot ruim boven de 11. Dat zal het moment geweest zijn van die presentatie van Jaap.
PB een dag te laat dus?
Zal dit de koers. Vandaag ruim boven de 11 sluiten als het mee zit.
Zou wel eens tot commentaar van de AFM kunnen leiden.
nogthans krijg ik niet makkelijk puts in bezit... puts?...jazeker, want wat eigenlijk omhoog zou moeten bij dit goede nieuws, gaat vaak contrair down. De ratten vd handel leven nog steeds (ik volg nu overigens WHV, dat net als CIO eerder dezelfde handelsfratsen vertoont...waarsch. shortsqueeze gaande, maar fundamenteel rijp voor de sloop vd koers) En als CRXL verder stijgt...ook goed, dan maar ietsje minder winst.
flinke weerstand op 11,50 31.500 stukjes.
nu nog maar 20K. Normaliter schrikt de markt van zo'n blok vooral bij een dalen aex.
weerstand is gebroken,op naar de 12 euro.
pardon schreef:
weerstand is gebroken,op naar de 12 euro.
€ 11,55....
pardon schreef:
weerstand is gebroken,op naar de 12 euro.
dat was ook gewoon met één klap erdoorheen. Ben benieuwd waar dit stopt vandaag en de komende dagen/weken!? Volgens mij wordt dit een stabiel doorgroeien qua koersniveau richting de 14 euro...
Groenspaan en Huppel: Houden jullie er rekening mee, dat met San Diego een tijdsverschil bestaat van 9 uur ten opzichte van ons?? En 3 uur met de andere kust van de VS?? Niks geen voorkennis en AFM. Koersverloop in VS gisteren hel;emaal vergelijkbaar met andere dagen.
Mr Greenspan schreef:
nu nog maar 20K.
Normaliter schrikt de markt van zo'n blok vooral bij een dalen aex.
even nagekeken: in 33 seconden waar we door die weerstand heen ;-) Zal wel één koop geweest zijn... 10:30:33 11,5100 41 10:30:23 11,5000 39 10:30:23 11,5000 500 10:30:23 11,5000 188 10:30:21 11,5000 250 10:30:18 11,5000 62 10:30:18 11,5000 438 10:30:14 11,5000 2628 10:30:14 11,5000 2926 10:30:14 11,5000 1000 10:30:14 11,5000 1311 10:30:13 11,5000 1500 10:30:09 11,5000 189 10:30:09 11,5000 1311 10:30:09 11,5000 689 10:30:09 11,5000 741 10:30:08 11,5000 9430 10:30:07 11,5000 1500 10:30:05 11,5000 1500 10:30:03 11,5000 1500 10:30:01 11,5000 1500 10:29:33 11,4900 1
CR6261 for influenza Thursday, 11 December 2008 The monoclonal antibody (mAb) directed against a broad range of influenza virus strains has strongly outperformed the most current anti-influenza drug in preclinical tests. Importantly, the study showed that CR6261 provides immediate protection against the influenza virus, suggesting that it will be able to prevent disease spread. In contrast, oseltamivir was less efficacious and in some cases not effective at all. The characterization of the antibody will be described in the online journal PLoS ONE on December 16, 2008. Link:http://cws.huginonline.com/C/132631/PR/200812/1276654_5_5.html Source:Crucell oseltamivir = Tamiflu van Roche! LONDON, Dec 11 (Reuters) - An experimental antibody drugagainst influenza from Crucell (CRCL.AS: Quote, Profile, Research, Stock Buzz) has stronglyoutperformed Roche’s (ROG.VX: Quote, Profile, Research, Stock Buzz) market-leading Tamiflu pill inpreclinical tests, the Dutch biotech firm said on Thursday. Crucell’s mAb CR6261 was tested against a number of flustrains, including the bird flu strain H5N1, which experts fearhas the potential to cause a pandemic in humans. The results were presented at an antibody engineeringconference in San Diego. Because Crucell’s product has yet to enter human tests, itis still many years away from reaching the market and may yetrun into unexpected hurdles in clinical trials. (Reporting by Ben Hirschler, editing by Will Waterman)
En de concurrentie zit ook niet stil. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans Thursday December 11, 6:30 am ET LAS VEGAS, Dec. 11 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL - News) today announced that the company's Vaxfectin®-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in the trial's higher dose cohorts. Vical researchers presented the expanded data, as well as new nonclinical data from the company's RapidResponse(TM) DNA vaccine manufacturing program, this week at the DNA Vaccines 2008 Conference (Las Vegas - December 9-11). H5N1 Pandemic Influenza Vaccine Phase 1 Trial Update New data presented at the conference indicates that the company's monovalent Vaxfectin®-formulated H5N1 pandemic influenza DNA vaccine induced T-cell responses against the H5 antigen in 75% to 100% of evaluable subjects in the various cohorts. T-cell responses could be important in protecting against serious disease and in limiting the spread of disease during an outbreak. The monovalent vaccine, which was based on the H5N1 influenza virus strain, A/Vietnam/1203/04, also induced antibody responses against the H5N1 influenza virus strain, A/Hong Kong/156/97 from a different clade, in 50% of responders. Cross-clade responses could be important in providing protection against emerging strains of influenza before a matching vaccine could be deployed. Antibody and/or T-cell responses against the matching H5 antigen and the conserved NP and M2 antigens were detected in a majority of subjects receiving the trivalent vaccine. Responses against conserved antigens could provide protection against serious disease or death during an outbreak of a new strain of influenza for which a vaccine had not yet been developed. Vical had previously reported that the monovalent vaccine achieved potentially protective levels of antibody responses (H5 hemagglutination inhibition, or HI, titers of at least 40 and at least a four-fold increase from baseline) in at least 50% and up to 67% of evaluable subjects in a 100-subject Phase 1 trial. In the two monovalent vaccine cohorts receiving the highest H5 DNA dose (1 mg), 80% to 100% of the responders had sustained responses through Day 182. Vical's monovalent vaccine contained a plasmid (a closed loop of DNA) encoding the hemagglutinin (HA) surface protein from the H5N1 influenza virus strain, A/Vietnam/1203/04. It was designed primarily to elicit antibody responses against the H5 protein but could elicit T-cell responses against H5 as well. Vical's trivalent vaccine contains the H5 plasmid plus separate plasmids encoding consensus sequences of two highly conserved influenza virus proteins: nucleoprotein (NP) and ion channel protein (M2). The trivalent vaccine was designed to elicit a combination of T-cell and antibody responses against all three proteins. Both vaccines were formulated with the company's Vaxfectin® adjuvant, which has demonstrated effectiveness with a variety of DNA vaccines in multiple animal models as well as dose-sparing and immune-enhancing ability in animals with a conventional seasonal influenza vaccine. RapidResponse(TM) DNA Vaccine Manufacturing Update New data presented at the current conference indicates that a single injection of a Vaxfectin®-formulated influenza vaccine produced by the company's RapidResponse(TM) manufacturing system provided complete protection of mice against challenge with highly lethal doses of H3N2 influenza virus. A dose response was apparent, as mice vaccinated with decreasing doses below a threshold level were afforded decreasing protection. The ratio of Vaxfectin® adjuvant to DNA in the vaccine also affected the protective efficacy of the vaccine. In separate tests, the use of alternative PCR primers, an integral part of the RapidResponse(TM) manufacturing process, did not significantly affect the protective efficacy of the resulting product. The RapidResponse(TM) system is designed to allow extremely rapid and large-scale production of DNA vaccines with low capital requirements. The company is proceeding with the development of the RapidResponse(TM) platform under the second year of grant funding awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Even kort door de bocht: Crucell Mabs: -preventief en therapeutisch -broad range of influenza virus strains -100% successful in preventing infection with H5N1 -Beter dan Tamiflu-blockbuster Vical: -2 strains worden genoemd -alleen preventief -at least 50% and up to 67%
oudje schreef:
Groenspaan en Huppel:
Houden jullie er rekening mee, dat met San Diego een tijdsverschil bestaat van 9 uur ten opzichte van ons??
En 3 uur met de andere kust van de VS??
Niks geen voorkennis en AFM. Koersverloop in VS gisteren hel;emaal vergelijkbaar met andere dagen.
Daar heb je gelijk in. Gelukkig maar.
gogogoo schreef:
-Beter dan Tamiflu-blockbuster
Eén van Tamiflu's bijeffecten: "In March 2007, Japan's Health Ministry warned that oseltamivir should not be given to those aged 10 to 19. The Ministry had previously decided, in May 2004, to change the literature accompanying oseltamivir to include neurological and psychological disorders as possible adverse effects, including: impaired consciousness, abnormal behavior, and hallucinations."en.wikipedia.org/wiki/Oseltamivir De weg is nog lang en andere bedrijven zitten inderdaad niet stil, maar als in de volgende fasen blijkt dat deze influenza MAb beter werkt en veiliger is dan de concurrent mag tzt een redelijk marktaandeel van een aardig stukje omzet worden verwacht. (Omzet Tamiflu 2007: ruim 2 miljard CHF) www.roche.com/gb07e04.pdf pag 8.
Was wel weer een mooi PB-tje vandaag . Ik had er alleen wel een beetje mixed feelings bij. OF ik ben helderziend OF wij wisten dit eigenlijk allemaal al. Ik meen mij te herinneren dat er al eerder bekend gemaakt was dat zowel H5N1 als H1N1 middels CR6261 geneutraliseerd kon worden . Maar goed , neemt niet weg dat Crucell in staat geweest is om een concept antilichaam vorm te gaan geven vanaf de "tekentafel" en er in preklinisch onderzoek geweldige resultaten mee heeft kunnen aantonen. De weg is nog heel lang van tekentafel naar daadwerkelijke productie en kan best onderweg wel blijken geen goed idee geweest te zijn. Wil even in herinnering brengen HIV vaccin van Merck... Kwam best wel ver in de onderzoeksfases en uiteindelijk niet echt een goed idee gebleken achteraf. WEL..... heel belangrijk ...... Crucell had toch een iets andere visie van hoe je dit vaccin zou moeten ontwikkelen en heeft daar achteraf RUIM gelijk in gekregen. Misschien vergis ik mij en haal ik dingen door elkaar, maar daar hebben we gelukkig dit forum voor .... Correct me if Iám wrong. Ian
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,79
+0,96%
EUR/USD
1,0713
+0,10%
FTSE 100
8.044,81
+0,26%
Germany40^
18.161,70
+0,13%
Gold spot
2.319,72
-0,10%
NY-Nasdaq Composite
15.696,64
+1,59%
Stijgers
Dalers